Cargando…

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Combination antiemetic regimens targeting multiple molecular pathways associated with emesis have become the standard of care for prevention of chemotherapy-induced nausea and vomiting (CINV) related to highly and moderately emetogenic chemotherapies. Antiemetic consensus guidelines from several pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hesketh, Paul J., Aapro, Matti, Jordan, Karin, Schwartzberg, Lee, Bosnjak, Snezana, Rugo, Hope
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573229/ https://www.ncbi.nlm.nih.gov/pubmed/26421300 http://dx.doi.org/10.1155/2015/651879

Ejemplares similares

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
por: Schwartzberg, Lee, et al.
Publicado: (2019)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
por: Aapro, M., et al.
Publicado: (2014)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
por: Zhang, L, et al.
Publicado: (2018)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
por: Clark-Snow, Rebecca, et al.
Publicado: (2017)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
por: Gralla, R. J., et al.
Publicado: (2014)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

The Antiemetic Mechanisms of Gingerols against Chemotherapy-Induced Nausea and Vomiting
por: Dai, Yongzhao, et al.
Publicado: (2022)

A Study on Utilization and Evaluation of Antiemetics in Chemotherapy-induced Nausea and Vomiting
por: Baburaj, Gayathri, et al.
Publicado: (2017)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
por: Palli, Swetha Rao, et al.
Publicado: (2015)

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Correction: Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
por: D’Souza, Anita, et al.
Publicado: (2020)

Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy
por: França, Monique Sedlmaier, et al.
Publicado: (2015)

Combination of Antiemetics for the Prevention of Postoperative Nausea and Vomiting in High-Risk Patients
por: Kim, Eun Jin, et al.
Publicado: (2007)

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic
por: Shetti, Akshaya N., et al.
Publicado: (2014)

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting
por: Alamri, Abdulrahman, et al.
Publicado: (2018)

Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study
por: Vazin, Afsaneh, et al.
Publicado: (2017)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
por: Celio, Luigi, et al.
Publicado: (2022)

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Dranitsaris, G., et al.
Publicado: (2017)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Assessment of the Relationship Between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy
por: Chan, Alexandre, et al.
Publicado: (2012)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9dosisutb94fa64econ8sokm76